Thromboembolic and bleeding risks in patients undergoing atrial fibrillation ablation: oral anticoagulation perspectives.

Abstract:

INTRODUCTION:Atrial fibrillation (AF) is a cause of significant morbidity and mortality. Catheter ablation for AF (CAAF) has emerged as an effective treatment option of rhythm control for patients with symptomatic AF. However, the risk of thromboembolism and bleeding in the periprocedural period represent a worrisome complication of this therapy. The reported incidence of thromboembolic and bleeding events associated with CAAF varies from 0.9% to 5% depending on the CAAF strategy and the anticoagulation regimen used in the periprocedural period. Areas covered: The different anticoagulation regimens used prior to, during, and after CAAF to minimize the risk of thromboembolic and bleeding events are reviewed. The use of uninterrupted oral anticoagulation and appropriate heparin dosing to achieve safe activated clotting time levels are also detailed. A comprehensive approach with assessment of individual risk for thromboembolic and bleeding complications, and understanding the pharmacokinetics of the anticoagulant agents available is also reviewed. Expert opinion: The key advances done in the periprocedural anticoagulation field include the use of uninterrupted anticoagulation strategies in patients undergoing AF ablation and efforts to simplify the selection of patients who need LAA thrombus screening prior to ablation.

journal_name

Expert Opin Drug Saf

authors

Briceño DF,Madan N,Romero J,Londoño A,Villablanca PA,Natale A,Di Biase L

doi

10.1080/14740338.2017.1325867

subject

Has Abstract

pub_date

2017-07-01 00:00:00

pages

769-777

issue

7

eissn

1474-0338

issn

1744-764X

journal_volume

16

pub_type

杂志文章,评审
  • Frequency of real-world reported adverse drug reactions in rheumatoid arthritis patients.

    abstract:OBJECTIVES:To describe the cumulative incidences of adverse drug reactions (ADRs) associated with disease-modifying anti-rheumatic drugs (DMARDs) in rheumatoid arthritis (RA) patients from real-world data (RWD), using the DREAM-RA registry, and to compare these with incidence frequencies mentioned in the Summary of Pro...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1080/14740338.2020.1830058

    authors: Giraud EL,Jessurun NT,van Hunsel FPAM,van Puijenbroek EP,van Tubergen A,Ten Klooster PM,Vonkeman HE

    更新日期:2020-12-01 00:00:00

  • Tazarotene foam, 0.1%, for the treatment of acne.

    abstract:INTRODUCTION:Acne is a common skin condition of the pilosebaceous units that affects the young and old, ranges from moderate to severe and can be treated with an array of options. Topical retinoids are the initial treatment for acne due to their ability to treat comedones, the starting point of acne. AREAS COVERED:Taz...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1517/14740338.2016.1117605

    authors: Smith JA,Narahari S,Hill D,Feldman SR

    更新日期:2016-01-01 00:00:00

  • Oral hypoglycemic agents for gestational diabetes mellitus?

    abstract:INTRODUCTION:Gestational diabetes mellitus (GDM), the most frequent medical complication of pregnancy, is associated with several adverse outcomes over the short- and long-term for both mother and offspring. Standard treatment for GDM consists of insulin injections. Oral hypoglycemic agents (OHAs), on the other hand, a...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2011.521740

    authors: Maymone AC,Baillargeon JP,Ménard J,Ardilouze JL

    更新日期:2011-03-01 00:00:00

  • Safety evaluation of trabectedin in treatment of soft-tissue sarcomas.

    abstract:INTRODUCTION:Trabectedin gained the approval by the European Medicines Agency (EMA) in 2007 for the treatment of patients affected by soft-tissue sarcomas (STS). Its safety and activity profiles have been assessed in many clinical trials as well as in standard clinical practice for > 10 years. AREAS COVERED:This artic...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2013.829037

    authors: Martin-Liberal J,Judson I

    更新日期:2013-11-01 00:00:00

  • Prescribing in 2019: what are the safety concerns?

    abstract:INTRODUCTION:Unintended harm from prescribing errors remains a prevalent concern in healthcare leading to significant morbidity and mortality around the world. Prescribers face new challenges to their practice in modern times such as increasingly complex health-care systems, an aging population with increasing multimor...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2019.1571038

    authors: Coleman JJ

    更新日期:2019-02-01 00:00:00

  • Influenza vaccination in patients with end-stage renal disease.

    abstract:INTRODUCTION:Patients with end-stage renal disease (ESRD) are considered at higher risk of influenza-related complications and are listed worldwide among the subjects for whom yearly influenza vaccination is strongly recommended. However, influenza vaccination coverage of patients with ESRD is significantly lower than ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2015.1053459

    authors: Principi N,Esposito S,ESCMID Vaccine Study Group (EVASG).

    更新日期:2015-08-01 00:00:00

  • Safety of epidural steroid injections.

    abstract:INTRODUCTION:Epidural steroid injections (ESI) are a commonly utilized treatment for cervical and lumbar radicular pain. All medical procedures and medications carry an inherent level of risk, that must be balanced with the effectiveness of the treatment to determine the risk to benefit ratio for a patient. AREAS COVE...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2016.1184246

    authors: Schneider B,Zheng P,Mattie R,Kennedy DJ

    更新日期:2016-08-01 00:00:00

  • Association of H1-antihistamines with torsade de pointes: a pharmacovigilance study of the food and drug administration adverse event reporting system.

    abstract::Background: This study aimed to measure the association of various H1-antihistamines (H1A) with Torsade de Pointes (TdP), and present a comprehensive overview of H1A-induced TdP cases reported to the Food and Drug Administration Adverse Event Reporting System (FAERS). Methods: All H1A-induced TdP cases (n = 406) were ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1080/14740338.2021.1846717

    authors: Ali Z,Ismail M,Khan F,Sajid H

    更新日期:2021-01-01 00:00:00

  • CGRP inhibitors for migraine prophylaxis: a safety review.

    abstract:INTRODUCTION:Since calcitonin gene-related peptide (CGRP) plays an important role in the pathophysiology of migraine via the activation of the trigeminovascular system, the newest prophylactic treatments directly block CGRP or its receptor. However, the safety of these novel antimigraine drugs is not yet sufficiently e...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1080/14740338.2020.1811229

    authors: Rivera-Mancilla E,Villalón CM,MaassenVanDenBrink A

    更新日期:2020-10-01 00:00:00

  • Safety and tolerability of antipsychotic-mood stabilizer co-treatment in the management of acute bipolar disorder: results from a systematic review and exploratory meta-analysis.

    abstract:INTRODUCTION:Mood stabilizer (MS) plus antipsychotic (AP) co-treatment is common in patients with acute bipolar disorder (BD), but adverse effects (AEs) of this strategy have not been systematically reviewed. AREAS COVERED:We conducted a systematic review searching PubMed/MEDLINE and PsycINFO on April 1, 2015 for rand...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,meta分析,评审

    doi:10.1517/14740338.2015.1053457

    authors: Galling B,Garcia MA,Osuchukwu U,Hagi K,Correll CU

    更新日期:2015-08-01 00:00:00

  • Drugs with anticholinergic properties: a potential risk factor for psychosis onset in Alzheimer's disease?

    abstract::Psychosis in Alzheimer's disease is common and troublesome. The impact on the quality of life of both patients and caregivers is high and drug treatments raise concern in terms of both efficacy and safety. Therefore, identifying the risk factors that play an important role in the onset of psychosis is mandatory for th...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740330903099636

    authors: Cancelli I,Beltrame M,D'Anna L,Gigli GL,Valente M

    更新日期:2009-09-01 00:00:00

  • High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions.

    abstract:INTRODUCTION:In 1998, high-dose interleukin-2 (IL-2) was the first immunotherapy approved for the treatment of metastatic melanoma based on durable objective responses documented in a subset of patients but widespread utilization was limited by significant toxicity. Advances in targeted therapy and the emergence of T c...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2017.1382472

    authors: Marabondo S,Kaufman HL

    更新日期:2017-12-01 00:00:00

  • Do we need to worry about mycophenolate overdose?

    abstract:INTRODUCTION:To discuss the significance of the recent observational case series from the Swiss Toxicological Information Centre (STIC). Mycophenolic acid (MPA) and its prodrug mycophenolate mofetil are immunosuppressive agents that are frequently prescribed in renal transplant recipients, and their safety profiles mus...

    journal_title:Expert opinion on drug safety

    pub_type: 评论,社论

    doi:10.1517/14740338.2014.905540

    authors: Filler G,Ferrand A

    更新日期:2014-05-01 00:00:00

  • Gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs.

    abstract::NSAIDs are used extensively worldwide at a cost of billions of dollars annu-ally. Adverse side effects, especially in the gastrointestinal (GI) tract, are uncommon but cause a substantial burden of illness because of the volume of use. Important upper GI complications include dyspepsia, gastric erosions and peptic ulc...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.4.2.157

    authors: Peng S,Duggan A

    更新日期:2005-03-01 00:00:00

  • Safety considerations when using drugs to treat pruritus.

    abstract::Introduction: Treatment for chronic pruritus ranges from use of topical formulations to newer biologic agents. Targeting treatment to the underlying etiology is key in reducing the burden of disease while avoiding systemic or adverse effects.Areas covered: This review details the effective medical treatments used in v...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2020.1728252

    authors: Fourzali K,Yosipovitch G

    更新日期:2020-04-01 00:00:00

  • The safety of available treatments options for neuroendocrine tumors.

    abstract:INTRODUCTION:Neuroendocrine neoplasms (NEN) represent a heterogeneous group of malignancies generally characterized by low proliferation and indolent course. However, about half of the newly diagnosed cases are metastatic and require long-term systemic therapies. Areas covered: This review revises the literature to sum...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2017.1354984

    authors: Faggiano A,Lo Calzo F,Pizza G,Modica R,Colao A

    更新日期:2017-10-01 00:00:00

  • An observational study of nasal cavity toxicity in cancer patients treated with bevacizumab.

    abstract:BACKGROUND:The nasal cavity is a vulnerable zone which may be damaged by vascular disorders. We systematically assessed the frequency and severity of nasal cavity alterations during bevacizumab treatment, to determine its clinical relevance and factors contributing to its onset. PATIENTS AND METHODS:We conducted a hos...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1517/14740338.2014.960388

    authors: D'Amico M,Pagano M,Pasa A,Puntoni M,Clavarezza M,Gennari A,Gozza A,Zanardi S,Defferrari C,Provinciali N,Campazzi E,Campora S,Paleari L,Marra D,Petrera M,DeCensi A

    更新日期:2014-11-01 00:00:00

  • Safety of carbonic anhydrase inhibitors.

    abstract:INTRODUCTION:Carbonic anhydrase (CA) inhibitors have an impressive safety record despite the multiple functions that CA isozymes serve because they are not fully inhibited with most dosing. While reducing the targeted CA-dependent process sufficiently for disease control, residual activity and uncatalyzed rates in comb...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2014.897328

    authors: Swenson ER

    更新日期:2014-04-01 00:00:00

  • Safety and tolerability of injectable lipid-lowering drugs: an update of clinical data.

    abstract:INTRODUCTION:Cardiovascular (CV) diseases are the leading cause of death and disability in the developed countries. Lipid-lowering therapy is a cornerstone of the CV risk modification strategy. The first line treatment for hyperlipidemia is statins, which decrease low-density lipoprotein cholesterol (LDL-C) by 30-50% a...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1080/14740338.2019.1620730

    authors: Strilchuk L,Fogacci F,Cicero AF

    更新日期:2019-07-01 00:00:00

  • Off-label and unlicensed prescribing for newborns and children in different settings: a review of the literature and a consideration about drug safety.

    abstract::This review aims to give an updated overview of the worldwide situation of off-label and unlicensed drug use in the paediatric field, also taking into account the safety of this kind of treatment. A Medline and Embase search was performed between 1990 and 2006 and a total of 52 studies were identified and included in ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.5.5.703

    authors: Cuzzolin L,Atzei A,Fanos V

    更新日期:2006-09-01 00:00:00

  • The role and efficacy of denosumab in the treatment of osteoporosis: an update.

    abstract:INTRODUCTION:Bone strength determinants such as bone mineral density and bone quality parameters are determined by life-long remodeling of skeletal tissue. Denosumab is a fully human mAb receptor activator of NF-κB ligand, which selectively inhibits osteoclastogenesis, the end product of a cascade interaction among num...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2010.516249

    authors: Charopoulos I,Orme S,Giannoudis PV

    更新日期:2011-03-01 00:00:00

  • Potentially inappropriate concomitant medicine use with the selective COX-2 inhibitor celecoxib: Analysis and comparison of spontaneous adverse event reports from Australia, Canada and the USA.

    abstract:BACKGROUND:To perform an international comparison and analysis of celecoxib spontaneous adverse event reports (AERs) from Canada, Australia and the United States, focusing on gastrointestinal, renal and cardiovascular events. This study also examined concomitant medicines use which may have potentiated the risk of the ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1080/14740338.2019.1589447

    authors: Baselyous Y,De Cocinis M,Ibrahim M,Kalra A,Yacoub R,Ahmed R

    更新日期:2019-03-01 00:00:00

  • Statin use and the risk of kidney cancer: a population-based case-control study.

    abstract:OBJECTIVE:To investigate whether the use of statins was associated with kidney cancer risk. METHODS:We conducted a population-based case-control study in Taiwan. Cases consisted of all patients who were aged 50 years and older, and had a first-time diagnosis of kidney cancer for the period between 2005 and 2009. The c...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1517/14740338.2012.678831

    authors: Chiu HF,Kuo CC,Kuo HW,Lee IM,Lee CT,Yang CY

    更新日期:2012-07-01 00:00:00

  • Adverse effects of golimumab in the treatment of rheumatologic diseases.

    abstract:INTRODUCTION:A number of new biological immune modulators have become available as treatments for inflammatory diseases over the past two decades. Most prominent among them are TNF-α inhibitors (TNFi) which have been available in the clinic since the late 1990s. TNFi have demonstrated efficacy in various rheumatologic ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2013.831403

    authors: Yang H,Kavanaugh A

    更新日期:2014-01-01 00:00:00

  • Safety and efficacy of paracetamol and NSAIDs in osteoarthritis: which drug to recommend?

    abstract:INTRODUCTION:Osteoarthritis (OA) is the most common form of arthritis and is a major cause of disability, especially in people ≥ 45 years old. Several international societies recommend the use of both acetaminophen and non-steroidal anti-inflammatory drugs (NSAIDs) to alleviate OA pain. However, patients with OA often ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.2015.1056776

    authors: Richette P,Latourte A,Frazier A

    更新日期:2015-08-01 00:00:00

  • Is it safe to use topical NSAIDs for corneal sensitivity in Sjögren's syndrome patients?

    abstract::Sjögren's syndrome dry eye is an inflammatory disease accompanied by an impairment of the autonomous nervous system of the ocular surface. The therapy for this condition is shifting from the mere tear replacement to a more complex approach including an anti-inflammatory treatment. Clinical trials have evidenced that t...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章,评审

    doi:10.1517/14740338.6.1.33

    authors: Aragona P,Di Pietro R

    更新日期:2007-01-01 00:00:00

  • Thrombotic microangiopathy associated with gemcitabine: rare but real.

    abstract::Gemcitabine-associated thrombotic thrombocytopenic purpura is a rare complication of gemcitabine treatment with an incidence ranging from 0.015 to 1.4%. Clinically, this disease manifests as haemolytic anaemia, thrombocytopenia and renal insufficiency; hypertension and neurological and pulmonary symptoms are also know...

    journal_title:Expert opinion on drug safety

    pub_type: 社论

    doi:10.1517/14740330902942299

    authors: Saif MW,Xyla V,Makrilia N,Bliziotis I,Syrigos K

    更新日期:2009-05-01 00:00:00

  • Counterfeit drugs: defining the problem and finding solutions.

    abstract::The problem of counterfeit drugs is increasingly becoming a top priority of drug regulatory agencies, licit pharmaceutical manufacturers and healthcare professionals, and is of rising concern among consumers. A review of the current literature reveals that counterfeiting is no longer isolated in developing nations, bu...

    journal_title:Expert opinion on drug safety

    pub_type: 社论

    doi:10.1517/14740338.4.4.619

    authors: Wertheimer AI,Santella TM

    更新日期:2005-07-01 00:00:00

  • Pegylated IFN-α-2a and ribavirin in the treatment of hepatitis C infection in children.

    abstract::The epidemiology, natural history and efficacy of treatment for chronic hepatitis C in children are presented. An increase in the number of vertical infections of this etiology is suggested. In children, especially in those vertically infected, spontaneous elimination of hepatitis C virus (HCV) is observed more often ...

    journal_title:Expert opinion on drug safety

    pub_type: 杂志文章

    doi:10.1517/14740338.2015.1005599

    authors: Pawlowska M

    更新日期:2015-03-01 00:00:00

  • The safety of methadone hydrochloride.

    abstract::Methadone is an interesting analgesic for multiple reasons. The unique properties of the agent, low cost and widespread availability have led to increases in methadone prescribing. Despite advantages, methadone is challenging to work with, particularly in patients with high opioid requirements. Recent concerns regardi...

    journal_title:Expert opinion on drug safety

    pub_type: 社论

    doi:10.1517/14740338.7.1.5

    authors: Swegle JM,Wensel DD

    更新日期:2008-01-01 00:00:00